Activity of meropenem-vaborbactam against carbapenem- resistant enterobacteriaceae in a murine model of pyelonephritis

William J. Weiss; Mark E. Pulse; Phung Nguyen; Kelly Peterson; Jessica Silva; Jerry W. Simecka; David Valtierra; Mojgan Sabet; David C. Griffith

doi:10.1128/AAC.01439-17

Activity of meropenem-vaborbactam against carbapenem- resistant enterobacteriaceae in a murine model of pyelonephritis

William J. Weiss, Mark E. Pulse, Phung Nguyen, Kelly Peterson, Jessica Silva, Jerry W. Simecka, David Valtierra, Mojgan Sabet, David C. Griffith

Pharmaceutical Sciences

Research output: Contribution to journal › Article › peer-review

11 Scopus citations

Abstract

The recently approved combination of meropenem and vaborbactam (Vabomere) is highly active against Gram-negative pathogens, especially Klebsiella pneumoniae carbapenemase (KPC)-producing, carbapenem-resistant Enterobacteriaceae. We evaluated the efficacy of meropenem-vaborbactam against three clinically relevant isolates in a murine pyelonephritis model. The data indicate that the combination of meropenem and vaborbactam significantly increased bacterial killing compared to that with the untreated controls. These data suggest that this combination may have utility in the treatment of complicated urinary tract infections due to KPCproducing, carbapenem-resistant Enterobacteriaceae.

Original language	English
Article number	e01439
Journal	Antimicrobial agents and chemotherapy
Volume	62
Issue number	1
DOIs	https://doi.org/10.1128/AAC.01439-17
State	Published - Jan 2018

Keywords

KPC
Klebsiella pneumoniae carbapenemase
Meropenem
Pyelonephritis
Vaborbactam

Access to Document

10.1128/AAC.01439-17

Link to publication in Scopus

Fingerprint Dive into the research topics of 'Activity of meropenem-vaborbactam against carbapenem- resistant enterobacteriaceae in a murine model of pyelonephritis'. Together they form a unique fingerprint.

Cite this

@article{612c6c4feb804032ad45fd0c39ea096b,

title = "Activity of meropenem-vaborbactam against carbapenem- resistant enterobacteriaceae in a murine model of pyelonephritis",

abstract = "The recently approved combination of meropenem and vaborbactam (Vabomere) is highly active against Gram-negative pathogens, especially Klebsiella pneumoniae carbapenemase (KPC)-producing, carbapenem-resistant Enterobacteriaceae. We evaluated the efficacy of meropenem-vaborbactam against three clinically relevant isolates in a murine pyelonephritis model. The data indicate that the combination of meropenem and vaborbactam significantly increased bacterial killing compared to that with the untreated controls. These data suggest that this combination may have utility in the treatment of complicated urinary tract infections due to KPCproducing, carbapenem-resistant Enterobacteriaceae.",

keywords = "KPC, Klebsiella pneumoniae carbapenemase, Meropenem, Pyelonephritis, Vaborbactam",

author = "Weiss, {William J.} and Pulse, {Mark E.} and Phung Nguyen and Kelly Peterson and Jessica Silva and Simecka, {Jerry W.} and David Valtierra and Mojgan Sabet and Griffith, {David C.}",

year = "2018",

month = jan,

doi = "10.1128/AAC.01439-17",

language = "English",

volume = "62",

journal = "Antimicrobial Agents and Chemotherapy",

issn = "0066-4804",

publisher = "American Society for Microbiology",

number = "1",

}

Activity of meropenem-vaborbactam against carbapenem- resistant enterobacteriaceae in a murine model of pyelonephritis. / Weiss, William J.; Pulse, Mark E.; Nguyen, Phung; Peterson, Kelly; Silva, Jessica; Simecka, Jerry W.; Valtierra, David; Sabet, Mojgan; Griffith, David C.

In: Antimicrobial agents and chemotherapy, Vol. 62, No. 1, e01439, 01.2018.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Activity of meropenem-vaborbactam against carbapenem- resistant enterobacteriaceae in a murine model of pyelonephritis

AU - Weiss, William J.

AU - Pulse, Mark E.

AU - Nguyen, Phung

AU - Peterson, Kelly

AU - Silva, Jessica

AU - Simecka, Jerry W.

AU - Valtierra, David

AU - Sabet, Mojgan

AU - Griffith, David C.

PY - 2018/1

Y1 - 2018/1

N2 - The recently approved combination of meropenem and vaborbactam (Vabomere) is highly active against Gram-negative pathogens, especially Klebsiella pneumoniae carbapenemase (KPC)-producing, carbapenem-resistant Enterobacteriaceae. We evaluated the efficacy of meropenem-vaborbactam against three clinically relevant isolates in a murine pyelonephritis model. The data indicate that the combination of meropenem and vaborbactam significantly increased bacterial killing compared to that with the untreated controls. These data suggest that this combination may have utility in the treatment of complicated urinary tract infections due to KPCproducing, carbapenem-resistant Enterobacteriaceae.

AB - The recently approved combination of meropenem and vaborbactam (Vabomere) is highly active against Gram-negative pathogens, especially Klebsiella pneumoniae carbapenemase (KPC)-producing, carbapenem-resistant Enterobacteriaceae. We evaluated the efficacy of meropenem-vaborbactam against three clinically relevant isolates in a murine pyelonephritis model. The data indicate that the combination of meropenem and vaborbactam significantly increased bacterial killing compared to that with the untreated controls. These data suggest that this combination may have utility in the treatment of complicated urinary tract infections due to KPCproducing, carbapenem-resistant Enterobacteriaceae.

KW - KPC

KW - Klebsiella pneumoniae carbapenemase

KW - Meropenem

KW - Pyelonephritis

KW - Vaborbactam

UR - http://www.scopus.com/inward/record.url?scp=85039804469&partnerID=8YFLogxK

U2 - 10.1128/AAC.01439-17

DO - 10.1128/AAC.01439-17

M3 - Article

C2 - 29038270

AN - SCOPUS:85039804469

VL - 62

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 1

M1 - e01439

ER -